Dual Temozolomide and ICI Treatment Is Efficacious and Safe in MSS mCRC

Skip Nav Destination

Article navigation

Research Watch| May 02 2022

Online Issn: 2159-8290

Print Issn: 2159-8274

2022

American Association for Cancer Research.

Cancer Discov (2022) 12 (5): 1181.

Abstract

Patients with MSS and MGMT-depleted mCRC exhibited clinical benefit post–temozolomide and ICI treatment.

2022

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.